Status:
COMPLETED
The Effect of Levetiracetam (Keppra) on the Treatment of Tremor in Multiple Sclerosis
Lead Sponsor:
Newcastle-upon-Tyne Hospitals NHS Trust
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-60 years
Brief Summary
We are carrying out this study to determine whether Keppra (a drug usually used to treat epilepsy) is an effective treatment for tremor in patients with Multiple Sclerosis. Tremor is one of the most c...
Detailed Description
Multiple Sclerosis is the most common inflammatory demyelinating disease of the CNS and is the leading cause of neurological disability in young adults in the UK (\~ 90,000 patients' affected). It has...
Eligibility Criteria
Inclusion
- McDonald criteria for diagnosis of MS (McDonald, 2001)15
- Clinical evidence of Cerebellar Tremor.
- Aged 18-60
Exclusion
- There is evidence of a further significant MS relapse during the trial
- Evidence of resting tremor, or Holmes (rubral) tremor
- Pregnant or breast feeding mothers
- Patients with inadequate understanding of the English language to comprehend the patient information sheet
- Evidence of any significant renal impairment
- History of epilepsy
Key Trial Info
Start Date :
February 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00430599
Start Date
February 1 2007
End Date
September 1 2009
Last Update
October 12 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sir James Spence Institute, Royal Victoria Infirmary
Newcastle, Tyne and Wear, United Kingdom, NE1 4LP